The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RX-5902: A phosphorylated p68 targeting agent to treat subjects with advanced solid tumors.
 
Martin Gutierrez
Consulting or Advisory Role - Bayer; Lilly
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Esanex (Inst); Gilead Sciences (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Rexahn Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
S. Gail Eckhardt
Stock and Other Ownership Interests - Entremed
Honoraria - Boehringer Ingelheim; Janssen Oncology; Kyowa Hakko Kirin; Lilly/ImClone
Consulting or Advisory Role - CASI Pharmaceuticals; OnKure; Pfizer; Sanofi; Suvica; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); cleave biosciences (Inst); Genentech (Inst); OncoMed (Inst); Rexahn Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Genentech; Kyowa Hakko Kirin; Lilly/ImClone; Sanofi
 
W Larry Gluck
No Relationships to Disclose
 
Ely Benaim
Employment - Berg Pharma; Rexahn Pharmaceuticals
Leadership - Berg Pharma; Rexahn Pharmaceuticals
Stock and Other Ownership Interests - Rexahn Pharmaceuticals